Effects of Type 1 Insulin-Like Growth Factor Receptor Silencing in a Human Adrenocortical Cell Line

Autor(es)

Ribeiro, T. C. ^[1] ; Jorge, A. A. ^{[1, 2]} ; Montenegro, L. R. ^[1] ; Almeida, M. Q. ^[1] ; Ferraz-de-Souza, B. ^[3] ; Nishi, M. Y. ^[1] ; Mendonca, B. B. ^[1] ; Latronico, A. C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Lab Hormonios & Genet Mol, Fac Med, Unidade Endocrinol Desenvolvimento, LIM 42, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Lab Endocrinol Celular & Mol, Fac Med, Unidade Endocrinol Genet, LIM 25, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Lab Carboidratos & Radioimunoensaios LIM 18, Unidade Doencas Osteometab, Disciplina Endocrinol & Metabol, Fac Med, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Hormone and Metabolic Research; v. 48, n. 7, p. 484-488, JUL 2016.
• Citações Web of Science: 2

Resumo

Type 1 insulin-like growth factor receptor (IGF-1R) is overexpressed in a variety of human cancers, including adrenocortical tumors. The aim of the work was to investigate the effects of IGF-1R downregulation in a human adrenocortical cell line by small interfering RNA (siRNA). The human adrenocortical tumor cell line NCI H295R was transfected with 2 specific IGF1R siRNAs (\#1 and \#2) and compared with untreated cells and a negative control siRNA. IGF1R expression was determined by quantitative reverse-transcription PCR (qRTPCR) and Western blot. The effects of IGF-1R downregulation on cell proliferation and apoptosis were assessed. IGF-1R levels were significantly decreased in cells treated with IGF1R siRNA \#1 or \#2. Relative expression of IGF1R mRNA decreased approximately 50 % and Western blot analysis revealed a 30 % of reduction in IGF-1R protein. Downregulation of this gene resulted in 40 % reduction in cell growth in vitro and 45 % increase in apoptosis using siRNA \#2. These findings demonstrate that decreasing IGF1R mRNA and protein expression in NCI H295R cells can partially inhibit adrenal tumor cell growth in vitro. Targeting IGF-1R is a promising therapy for pediatric malignant adrenocortical tumor and can still be an option for adult adrenocortical cancer based on personalized genomic tumor profiling. (AU)

• Processo FAPESP: 10/09503-7 - Análise dos Efeitos do Silenciamento Gênico de IGF1R em Linhagens de Tumores Adrenocorticais Humanos
• Beneficiário: Tamaya Castro Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Doutorado